Are you Dr. Hayslip?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 46 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
800 Rose Street Cc180a Roach Bldg.
Uk Hematology Clinic
Lexington, KY 40536Phone+1 859-257-6006Fax+1 859-257-6002
Summary
- Dr. John Hayslip, MD is an oncologist in Lexington, Kentucky. He is currently licensed to practice medicine in Kentucky. He is affiliated with The OSUCCC - James and is an Associate Professor at University of Kentucky College of Medicine.
Education & Training
Medical University of South CarolinaFellowship, Hematology and Medical Oncology, 2004 - 2007
Summa Health System/NEOMEDResidency, Internal Medicine, 2001 - 2004
Northeast Ohio Medical UniversityClass of 2001
Certifications & Licensure
KY State Medical License 2007 - 2015
Clinical Trials
- Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Oct 01
- High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLL Start of enrollment: 2009 Mar 01
- Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release Start of enrollment: 2010 Sep 01
Publications & Presentations
PubMed
- 1 citationsAuthor Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapyAndrew H. Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, V. E. Ivanov
Blood Cancer Journal. 2021-10-26 - 21 citations6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).Andrew H. Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, V. E. Ivanov
Blood Cancer Journal. 2021-10-01 - 40 citationsSafety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study.Sven de Vos, John P. Leonard, Jonathan W. Friedberg, Jasmine Zain, Kieron Dunleavy
Leukemia & Lymphoma. 2021-03-21
Press Mentions
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual MeetingOctober 17th, 2024- Pancreatic Cancer on the Rise: How Biotech Firms Are Developing Groundbreaking TreatmentsJune 12th, 2024
- Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib plus Defactinib in Combination with Gemcitabine and Nab-Paclitaxel in First-Line Metastatic Pancreatic CancerMay 24th, 2024
